WO2000047612A3 - Techniques de criblage a base de structure permettant de decouvrir un medicament - Google Patents

Techniques de criblage a base de structure permettant de decouvrir un medicament Download PDF

Info

Publication number
WO2000047612A3
WO2000047612A3 PCT/US2000/003665 US0003665W WO0047612A3 WO 2000047612 A3 WO2000047612 A3 WO 2000047612A3 US 0003665 W US0003665 W US 0003665W WO 0047612 A3 WO0047612 A3 WO 0047612A3
Authority
WO
WIPO (PCT)
Prior art keywords
naturally occurring
cell surface
drug discovery
surface receptor
screening techniques
Prior art date
Application number
PCT/US2000/003665
Other languages
English (en)
Other versions
WO2000047612A2 (fr
Inventor
Peizhi Luo
Bassil Dahiyat
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc filed Critical Xencor Inc
Priority to JP2000598528A priority Critical patent/JP2002540384A/ja
Priority to AU28808/00A priority patent/AU2880800A/en
Priority to CA002362541A priority patent/CA2362541A1/fr
Priority to EP00907284A priority patent/EP1153295A2/fr
Publication of WO2000047612A2 publication Critical patent/WO2000047612A2/fr
Publication of WO2000047612A3 publication Critical patent/WO2000047612A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/746—Erythropoetin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne de nouveaux analogues de récepteur de surface cellulaire d'origine non naturelle, des analogues de ligand, et des acides nucléiques codant pour ceux-ci. L'invention concerne également des techniques de criblage d'analogues de ligand et d'agents bioactifs capables de moduler l'activité de signalisation d'un analogue de récepteur de surface cellulaire d'origine non naturelle ou de se lier audits analogues de récepteur de surface cellulaire d'origine non naturelle.
PCT/US2000/003665 1999-02-11 2000-02-11 Techniques de criblage a base de structure permettant de decouvrir un medicament WO2000047612A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000598528A JP2002540384A (ja) 1999-02-11 2000-02-11 構造ベースでの薬効物質スクリーニング法
AU28808/00A AU2880800A (en) 1999-02-11 2000-02-11 Structure-based screening techniques for drug discovery
CA002362541A CA2362541A1 (fr) 1999-02-11 2000-02-11 Techniques de criblage a base de structure permettant de decouvrir un medicament
EP00907284A EP1153295A2 (fr) 1999-02-11 2000-02-11 Techniques de criblage a base de structure permettant de decouvrir un medicament

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12000999P 1999-02-11 1999-02-11
US60/120,009 1999-02-11
US13167499P 1999-04-29 1999-04-29
US60/131,674 1999-04-29

Publications (2)

Publication Number Publication Date
WO2000047612A2 WO2000047612A2 (fr) 2000-08-17
WO2000047612A3 true WO2000047612A3 (fr) 2000-12-14

Family

ID=26817948

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/003665 WO2000047612A2 (fr) 1999-02-11 2000-02-11 Techniques de criblage a base de structure permettant de decouvrir un medicament

Country Status (5)

Country Link
EP (1) EP1153295A2 (fr)
JP (1) JP2002540384A (fr)
AU (1) AU2880800A (fr)
CA (1) CA2362541A1 (fr)
WO (1) WO2000047612A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8457903B1 (en) 1999-01-19 2013-06-04 Codexis Mayflower Holdings, Llc Method and/or apparatus for determining codons
US7873477B1 (en) 2001-08-21 2011-01-18 Codexis Mayflower Holdings, Llc Method and system using systematically varied data libraries
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
AU2003284260B2 (en) * 2002-10-11 2010-06-03 Zymogenetics, Inc. Production of homotrimeric fusion proteins
AU2004270774A1 (en) * 2003-09-05 2005-03-17 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
US7786261B2 (en) 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0638787A (ja) * 1992-03-04 1994-02-15 Snow Brand Milk Prod Co Ltd 可溶性エリスロポエチン受容体蛋白質、およびそのアミノ酸配列をコードする遺伝子
US5292654A (en) * 1990-12-13 1994-03-08 Whitehead Institute For Biomedical Research Mutant EPO receptor and uses therefor
WO1994029458A1 (fr) * 1993-06-07 1994-12-22 Amgen Inc. Molecules receptrices hybrides
EP0742438A2 (fr) * 1995-05-10 1996-11-13 Bayer Corporation Triage de librairie peptidiques combinatoires pour sélection de ligand peptidique utile à la purification d'affinité des protéines cibles
WO1998047089A1 (fr) * 1997-04-11 1998-10-22 California Institute Of Technology Dispositif et methode permettant une mise au point informatisee de proteines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292654A (en) * 1990-12-13 1994-03-08 Whitehead Institute For Biomedical Research Mutant EPO receptor and uses therefor
JPH0638787A (ja) * 1992-03-04 1994-02-15 Snow Brand Milk Prod Co Ltd 可溶性エリスロポエチン受容体蛋白質、およびそのアミノ酸配列をコードする遺伝子
WO1994029458A1 (fr) * 1993-06-07 1994-12-22 Amgen Inc. Molecules receptrices hybrides
EP0742438A2 (fr) * 1995-05-10 1996-11-13 Bayer Corporation Triage de librairie peptidiques combinatoires pour sélection de ligand peptidique utile à la purification d'affinité des protéines cibles
WO1998047089A1 (fr) * 1997-04-11 1998-10-22 California Institute Of Technology Dispositif et methode permettant une mise au point informatisee de proteines

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BARBONE, F.P. ET AL.: "Mutagenesis Studies of the Human Erythropoietin Receptor", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 8, 21 February 1997 (1997-02-21), pages 4985 - 4992, XP000929145 *
DAHIYAT B I ET AL: "PROTEIN DESIGN AUTOMATION", PROTEIN SCIENCE,GB,CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, vol. 5, no. 5, 1 May 1996 (1996-05-01), pages 895 - 903, XP002073372, ISSN: 0961-8368 *
EDDINGTON, S.M.: "Superfamily Structure and Biotech Drug Development", BIOTECHNOLOGY, vol. 10, no. 12, December 1992 (1992-12-01), pages 1529 - 1534, XP000929407 *
JOHNSON, D.L. ET AL.: "Refolding, Purification, and Characterization of Human Erythropoietin Binding Protein Produced in Escherichia coli", PROTEIN EXPRESSION AND PURIFICATION, vol. 7, no. 1, February 1996 (1996-02-01), pages 104 - 113, XP000925310 *
JOLLIFFE, L.K. ET AL.: "Erythropoietin receptor: application in drug development", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 10, 1995, pages 28 - 34, XP000925308 *
LIVNAH, O. ET AL.: "An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation", NATURE STRUCTURAL BIOLOGY, vol. 5, November 1998 (1998-11-01), pages 993 - 1004, XP000925258 *
MCCONNELL, S.J. ET AL.: "Isolation of Erythropoietin Receptor Agonist Peptides Using Evolved Phage Libraries", BIOLOGICAL CHEMISTRY, vol. 379, October 1998 (1998-10-01), pages 1279 - 1286, XP000925403 *
MIDDLETON, S.A. ET AL.: "Critical Erythropoietin (EPO) Binding Determinants on the EPO Receptor Also Interact with an EPO Mimetic Peptide", BLOOD, vol. 88, no. 10, 15 November 1996 (1996-11-15), pages 661a, XP000925311 *
PATENT ABSTRACTS OF JAPAN vol. 018, no. 257 (C - 1200) 17 May 1994 (1994-05-17) *
QUELLE, D.E. ET AL.: "Mutations in the WSAWSE and Cytosolic Domains of the Erythropoietin Receptor Affect Signal Transduction and Ligand Binding and Internalization", MOLECULAR AND CELLULAR BIOLOGY, vol. 12, no. 10, October 1992 (1992-10-01), pages 4553 - 4561, XP000925397 *
WRIGHTON, N.C. ET AL.: "Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin", SCIENCE, vol. 273, 5 July 1996 (1996-07-05), pages 458 - 463, XP000925371 *

Also Published As

Publication number Publication date
WO2000047612A2 (fr) 2000-08-17
EP1153295A2 (fr) 2001-11-14
AU2880800A (en) 2000-08-29
JP2002540384A (ja) 2002-11-26
CA2362541A1 (fr) 2000-08-17

Similar Documents

Publication Publication Date Title
EP1140086A4 (fr) N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines
AU2002357692A1 (en) Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
HK1039942A1 (en) Piperdines as ccr5 modulators.
AU2482100A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU3126700A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
GC0000117A (en) Ccr5 modulators.
HK1054032A1 (zh) N-酰脲異環烷-六氫吡啶作為化學增活受者活動的抑揚調節劑
AU2002241724A1 (en) Diamines as modulators of chemokine receptor activity
EG21245A (en) Catalyst composition for the production of olefin polymers
AU2056700A (en) 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
HUP0203753A3 (en) Trans olefinic glucokinase activators, process for their preparation and their use
AU5600100A (en) Cyclopentyl modulators of chemokine receptor activity
ZA9811759B (en) Novel indole derivatives, processes for their preparation, their use and pharmaceutical compositions containing them.
AU2002326948A1 (en) Piperizinones as modulators of chemokine receptor activity
AU5809100A (en) Stabilitats-, biokompatibilitats-optimiertes adjuvans (sba) zur erhohung der humoralen und zellularen immunantwort
WO2000066730A3 (fr) Laminine 2 et ses methodes d'utilisation
AU1201401A (en) Benzylcycloalkyl amines as modulators of chemokine receptor activity
ZA9711222B (en) Olefin polymerization catalyst composition having increased activity.
CA2328133A1 (fr) Facteurs affectant l'activite de l'enzyme liberant le recepteur du facteur de necrose tumorale
AU5473800A (en) Cyclopentyl modulators of chemokine receptor activity
AU5473400A (en) Cyclopentyl modulators of chemokine receptor activity
AU7135901A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000047612A3 (fr) Techniques de criblage a base de structure permettant de decouvrir un medicament
WO2003020892A3 (fr) Acides nucleiques et polypeptides bv8 a activite mitogene
WO2004081229A3 (fr) Compositions a activite hematopoietique et immunitaire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2362541

Country of ref document: CA

Ref country code: CA

Ref document number: 2362541

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 598528

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 28808/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000907284

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000907284

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000907284

Country of ref document: EP